TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04200469

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative Flow Ratio (QFR) measurement
Description: Quantitative flow ratio (QFR) is a novel approach enabling rapid computation of FFR pullbacks from three-dimensional quantitative coronary angiography (3D-QCA) without using a pressure wire.
Study: NCT04946578

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: 6 weeks of prebiotic supplementation twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 weeks of maltodextrin supplementation twice a day
Study: NCT02388347

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7836 Dose 1
Description: Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7836 Dose 2
Description: Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7836 Dose 3
Description: Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI7836 Dose 4
Description: Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
Study: NCT00554996

Intervention type: DEVICE
Group type: OTHER
Intervention: E. coli 83972 coated urinary catheter
Description: E. coli 83972 coated urinary catheter
Study: NCT00609856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: tablet, 30 mg, once daily, 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: subcutaneous injection, start dose 6-10 units, once daily, 26 weeks
Study: NCT02796768

Intervention type: OTHER
Intervention: 3D US Scanning
Description: 3D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.

Intervention type: OTHER
Intervention: 2D US Scanning
Description: 2D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
Study: NCT01641653

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 2cc. one dose prior to OR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 1-2.5 mg
Study: NCT04281251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde appendicitis therapy
Description: Colonoscopy would be introduced until visualization of the appendiceal orifice. Catheter would be placed in the appendix and decompression performed. After removal of appendicolith, plastic stent would be placed for drainage of appendix.~For patients successfully treated with initial endoscopic drainage, they would be re-admitted at 1 weeks after index procedure for repeat colonoscopy. After reaching the appendiceal orifice, the previous plastic stent would be removed. A contrast appendicogram would be repeated by introducing a wire-guided catheter in the appendix, and any residual fecalith would be removed. Finally, a repeat contrast appendicogram would be performed to confirm complete clearance of fecalith.
Study: NCT03890198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-C182A cells
Description: Patients receive fludarabine (3×300 mg/ m\^2) and cyclophosphamide (3×30 mg/m\^2) IV on days -5 to-3, and then Patients receive CAR-T cells. PS：The specific dose of fludarabine and cyclophosphamide is adjusted according to the individual condition of the subject and the judgment of the investigator.
Study: NCT01893489

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 68Gallium-MSA
Description: 68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 68Gallium-MSA
Description: 68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging
Study: NCT02270671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABMT
Description: Attention Bias Modification Training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Training
Study: NCT02881372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral food desensitization
Description: The child's specific food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C). This oral spray solution will need to be administered twice a day, every day for a total of 4 months
Study: NCT03348410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Motivational interviewing with insurance officer
Study: NCT04266015

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral nutrition formula
Description: Intervention group will receive nasogastric feeding with commercially available liquid enteral diet (250 ml/can, Kcal/ml, 10.4 g protein/can) during free flap reconstruction at feeding rates 10-30 ml/h.
Study: NCT02081014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen Mini™ (glucagon injection)
Description: stable, pre-mixed, liquid glucagon for subcutaneous injection
Study: NCT03313492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UV4.me2
Description: UV4.me2 is an enhanced version of the original UV4.me web intervention and features the many of the same educational material and interactive components. New features/strategies for reach, effectiveness, and implementation include:~1. A mobile version of the site~2. Incentives in the form of clickable coupons and links to free samples for sun protection products (e.g., sunscreen)~3. Behavioral tracking and feedback, where users can set goals, track their progress, and receive tailored feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UV4.me
Description: Original version of the UV4.me website, which offers education and tailored responses to interactive quizzes about current sun protective behaviors and barriers to engaging in sun protective behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-Pamphlet
Description: A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society). Includes information on skin cancer risk and prevention.
Study: NCT01490892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3D HI and SHI of UCA
Description: Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
Study: NCT02980276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: Women randomised to the metformin group will receive metformin 500mg once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of 2500mg Metformin daily (5 tablets) or maximum tolerated dose, in addition to usual care (exercise and MNT), and taken until delivery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women randomised to the placebo group will receive 1 placebo tablet once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of five placebo tablets daily, in addition to usual care (exercise and MNT), and taken until delivery.
Study: NCT03430622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTP Plus
Description: LTP Plus is comprised of two components; Learning through play (LTP) and Interpersonal Psychotherapy (IPT). The LTP Plus is a low-literacy; sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Interpersonal Psychotherapy (IPT) intervention is comprised of a supportive element, an educational element, a parenting element and an interpersonal relationship element. Intervention goals include helping mothers feel supported, empowered and confident about their parenting abilities, which would directly influence reduction in depressive symptoms as well as resolution of interpersonal conflicts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: This group will be on their routine care and will not be given any intervention
Study: NCT02061878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Description: Marketed product Targretin® soft gelatin capsule (75mg/capsule) is over-encapsulated in a size AA-el Swedish orange capsule. The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
Study: NCT00667459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRESTIGE® LP Cervical Disc
Description: The PRESTIGE® LP Cervical Disc was inserted into the intervertebral disc space of the cervical spine using the anterior surgical approach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATLANTIS Anterior Cervical Plate
Description: Anterior cervical discectomy and fusion with ATLANTIS plate for control group
Study: NCT01122875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MFGR1877S
Description: Intravenous repeating dose
Study: NCT00078377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil 250 mg once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Armodafinil 150 mg once daily in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets once daily
Study: NCT02354651

Intervention type: OTHER
Intervention: Diaphragm conditioning via phrenic nerve stimulation
Description: Diaphragm pacing will be prescribed by the patient's clinical team.
Study: NCT00883974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensitivity Training
Description: The parent sensitivity training program was delivered in NICU (9 sessions) with a home-booster session. Therapists worked with parents following a manualized protocol. Targets of intervention included: recognizing signs of infant stress, shut-down mechanisms, alert-available behavior, motor behaviors, facial expressions,posture/muscle tone; graded stimulation; how to optimize interactions; touch, movement and massage; kangaroo care (nesting infants skin-to-skin against their mother); vocal, visual and multi-sensory stimulation; normalizing parental feelings; challenging dysfunctional thinking, and diary keeping.
Study: NCT01381575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV vaccine 580299
Description: Subjects received 2 or 3 doses of HPV vaccine administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals' HPV vaccine 580299
Description: Subjects received 2 or 3 doses of HPV vaccine administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV vaccine 580299
Description: Subjects received 2 or 3 doses of HPV vaccine administered intramuscularly.
Study: NCT03112915

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quadratus lumborum block
Description: QLB: Quadratus lumborum block : 20 mL of 0.25% bupivacaine will be administered between the quadratus lumborum and the psoas major muscle bilaterally in the lateral decubitus position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plan block
Description: TAP: transversus abdominis plan block: 20 mL of 0.25% bupivacaine will be administered between the internal oblique muscle and the transversus abdominis muscle bilaterally in the supine position
Study: NCT04697134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conscious Discipline-Based Environmental Enrichment Intervention
Description: Conscious Discipline, a social-emotional skills-based learning program that draws on current brain research and fosters enhanced connections between parents and their children.
Study: NCT01443403

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets administered orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Naldemedine tablets administered orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Naldemedine tablets administered orally once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naldemedine
Description: Naldemedine tablets administered orally once a day.
Study: NCT02344875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981, (Oral single dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981, (Oral single dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981, (Oral single dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981, (Oral single dosing)
Study: NCT01529489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resisted/Aerobic physical training
Description: COPD, aerobic physical training in cicloergometer, resisted physical training in cicloergometer, oxygen uptake kinetic, heart rate kinetic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interval physical training in elliptical equipament
Description: Control group (healthy individuals), interval physical training, elliptical equipment, oxygen uptake kinetic, heart rate kinetic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval physical training in elliptical equipament
Description: COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resisted/Aerobic physical training
Description: Control group, aerobic physical training in cicloergometer, resisted physical training in leg-press oxygen uptake kinetic heart rate kinetic
Study: NCT04834713

Intervention type: OTHER
Intervention: clinical classification of HFRS
Description: Based upon clinical classification of HFRS , the patients were classified into four types

Intervention type: OTHER
Intervention: clinical classification of HFRS
Description: Based upon clinical classification of HFRS , the patients were classified into four types

Intervention type: OTHER
Intervention: clinical classification of HFRS
Description: Based upon clinical classification of HFRS , the patients were classified into four types

Intervention type: OTHER
Intervention: clinical classification of HFRS
Description: Based upon clinical classification of HFRS , the patients were classified into four types
Study: NCT00803192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine Tablets, 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Famotidine Tablets, 40 mg
Study: NCT03680339

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean section
Description: CS will be done by pfannenstiel incision , transverse lower uterine segment incision ,immediate cord clamping after delivery of baby , closure of uterus by 2 layers , closure of abdomen in layers

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean section
Description: CS will be done by pfannenstiel incision , transverse lower uterine segment incision ,immediate cord clamping after delivery of baby , closure of uterus by 2 layers , closure of abdomen in layers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 10 IU of oxytocin with fetal delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 10 IU of oxytocin with fetal delivery
Study: NCT03065140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training or detraining
Description: A period of detraining or a supervised exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training or detraining
Description: A period of detraining or a supervised exercise program.
Study: NCT00725712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089 (formerly XL880)
Description: c-MET tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089 (formerly XL880)
Description: c-MET tyrosine kinase inhibitor
Study: NCT00598845

Intervention type: PROCEDURE
Intervention: Tumor biopsy study
Description: Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.
Study: NCT02509949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT02710331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Dronabinol
Description: 10 mg capsule of Dronabinol will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Dronabinol
Description: 10 mg capsule of Dronabinol will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: no alcohol, administered for \~80 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: no alcohol, administered for \~80 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: Placebo pill (no active cannabinoids) administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: Placebo pill (no active cannabinoids) administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Ethanol
Description: Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Ethanol
Description: Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
Study: NCT00757224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidance
Description: Smoking parents will receive education on the association between parental smoking and respiratory morbidity in the infant. They will also be offered ways to reduce smoke exposure of their infants.
Study: NCT02960503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Study participants will be randomized to the treatment arm (azithromycin 500 mg three times a week for 6 months).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be randomized to the control arm (placebo three times a week for 6 months).
Study: NCT01367847

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Helping the Noncompliant Child (HNC)
Description: Well-established behavioral parent training program (McMahon \& Forehand) for parents of 3 to 8 y.o. children with externalizing problems

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-Enhanced Helping the Noncompliant Child (TE-HNC)
Description: Standard HNC program plus technology-enhancements (see description under Arm)
Study: NCT03192345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR439459
Description: Pharmaceutical form: powder for solution for infusion~Route of administration: intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR439459
Description: Pharmaceutical form: powder for solution for infusion~Route of administration: intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR439459
Description: Pharmaceutical form: powder for solution for infusion~Route of administration: intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR439459
Description: Pharmaceutical form: powder for solution for infusion~Route of administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion
Study: NCT04511624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose1
Description: Drug: IBI112 SC dose1 Drug:placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose2
Description: Drug: IBI112 SC dose2 Drug:placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose3
Description: Drug: IBI112 SC dose3 Drug:placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose4
Description: Drug: IBI112 SC dose4 Drug:placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose5
Description: Drug: IBI112 IV dose5 Drug:placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose6
Description: Drug: IBI112 SC dose6 Drug:placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose7
Description: Drug: IBI112 IV dose7 Drug:placebo
Study: NCT03428308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening
Description: Each individual general practitioner reviews his/her record system and detects patients who meet the inclusion criteria. Patients who meet these criteria will be invited to participate in the project.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Patients who are diagnosed with one or more of the selected somatic diseases receive an individualized course of treatment in general practice, primarily focusing on initiation and maintenance of medical treatment, and complying with current clinical guidelines and course programmes. Treatment goals are set in active co-operation with the patient and his/her family and with supervision and support from the Mental Health Centre Copenhagen, clinical pharmacologists and relevant staff from the municipality in terms of contact/support persons.
Study: NCT01439386

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: PVAI with or without CTI ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: CTI ablation only